CARMAT : French gender equality index

French gender equality index

Year 2021

Complying with the Avenir law (September 5, 2018), CARMAT (France) S.A. publishes its gender equality index. This law aims to eliminate all gender pay disparities in France.

Scoring on a total of 100 points, this index allows companies to assess compensation equality between men and women. It is calculated on the basis of 5 criteria.

CARMAT (France) S.A. scores a total of 96 points for year of reference (January 1, 2020 to December 31, 2020). THE RESULT OF A PROACTIVE POLICY TO FIGHT FOR PROFESSIONAL EQUALITY.

About CARMAT: the world's most advanced total artificial heart

A credible response to end-stageheart failure: CARMAT aims to provide a response to a major public

health issue associated with heart disease, the world's leading cause of death: advanced heart failure. Thanks to its total artificial heart, Aeson®, composed of an implantable bioprosthesis and its portable external power supply system to which it is continuously connected, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from irreversible end- stage heart failure, the most seriously affected of the 20 million patients with this progressive disease in Europe and the United States.

The result of combining two types of unique expertise: the medical expertise of Professor Carpentier, known throughout the world for inventing Carpentier-Edwards®heart valves, which are the most used in the world, and the technological expertise of Airbus Group, world aerospace leader.

The first physiologic heart replacement therapy: given the use of highly biocompatible materials, its unique self-regulation system and its pulsatile nature, the Aeson® heart constitutes a new therapeutic class

• Physiologic Heart Replacement Therapy (PHRT) - and could save the lives of thousands of patients every year without risk of rejection and with a good quality of life. Aeson® is commercially available in the bridge- to-transplant indication in Europe and other countries that recognise the CE mark. Aeson® is also currently being evaluated in an Early Feasibility Study in the United-States.

For more information: www.carmatsa.com